Curevac announces financial results for the second quarter and first half of 2023 and provides business update
Initiated phase 2 study in covid-19 with monovalent and bivalent, modified mrna vaccine candidates; continued execution on infectious disease development program in collaboration with gsk initiated phase 1 study of cancer vaccine candidate, cvgbm, for surgically resected glioblastoma; recruitment of second dose cohort well on track broadened position in patent litigations by expanding the scope and asserting new intellectual property rights in germany and the u.s. public hearing held before the regional court dÜsseldorf as part of german patent litigation against pfizer/biontech cash and cash equivalents position of €537.9 million as of june 30, 2023 tÜbingen, germany and boston, ma / accesswire / august 17, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced financial results for the second quarter and first half of 2023 and provided a business update.
CVAC Ratings Summary
CVAC Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission